Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

Authors :: Meyer B
Clifton S
Locke W
Luu PL
Du Q
Lam D
Armstrong NJ
Kumar B
Deng N
Harvey K
Swarbrick A
Ganju V
Clark SJ
Pidsley R
Stirzaker C
Source :: Clinical epigenetics [Clin Epigenetics] 2021 Dec 18; Vol. 13 (1), pp. 226. Date of Electronic Publication: 2021 Dec 18.
Publication Year :: 2021
Abstract: Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient's response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC.<br /> (© 2021. The Author(s).)

Subjects :: Adult
Biomarkers, Tumor genetics
DNA Methylation genetics
Female
Humans
Middle Aged
Neoadjuvant Therapy methods
Neoadjuvant Therapy statistics & numerical data
Prognosis
Proportional Hazards Models
Triple Negative Breast Neoplasms etiology
Biomarkers, Pharmacological analysis
Biomarkers, Tumor analysis
Neoadjuvant Therapy standards
Triple Negative Breast Neoplasms drug therapy

Full Text Access

Tools